Kevin Dunleavy is a staff writer for Fierce Pharma, with his work also appearing in Herald-Mail Media and Yahoo Sports. Kevin specializes in covering the pharmaceutical industry, reporting on FDA approvals, drug developments, mergers and acquisitions, and other relevant news within the field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Kevin Dunleavy's coverage revolves around the healthcare and pharmaceutical industry, focusing on regulatory approvals, drug development, M&A activities, and legal settlements. His articles often cite data and press releases to support the information presented.
Given his focus on regulatory approvals and drug developments, Kevin may be interested in receiving pitches related to new drugs or treatments entering clinical trials or seeking FDA approval. Additionally, he might be interested in insights from experts who can provide analysis of pharmaceutical market trends supported by relevant data.
As Kevin's geographic focus is not specified but given the international nature of pharmaceutical companies' operations and regulations, sources with a global perspective on healthcare and pharmaceuticals are likely to resonate with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Kevin Dunleavy
Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen.
By: Kevin Dunleavy
Sanofi and Regeneron’s highly anticipated approval of Dupixent to treat chronic obstructive pulmonary disease (COPD) could be delayed, Regeneron CEO Len Schleifer said on Thursday.
This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year.
By: Kevin Dunleavy
During the Q&A portion of Amgen's quarterly conference call Thursday, eight of the first nine questions were about the company's investigational efforts in obesity.
Amneal Pharmaceuticals has agreed to pay $272.5 million to settle approximately 900 lawsuits brought by state, local and Native American jurisdictions
By: Kevin Dunleavy
In its opening months, after spinning off as a separate business from Novartis, Sandoz is riding the wave of a strong launch of its biosimilar version of AbbVie’s Humira (adalimumab).
By: Kevin Dunleavy
Once hailed as a landmark accomplishment for the speed with which it was developed and a shining example of British innovation, the AstraZeneca coronavirus vaccine has been grounded by the European Medicines Agency (EMA).
By: Kevin Dunleavy
Following the lead of French pharmaceutical giant Sanofi, Pfizer has agreed to settle more than 10,000 personal-injury claims from users of its
By: Kevin Dunleavy
Five months out from their twin FDA approvals in sickle cell disease (SCD), who’s winning the race to treat patients with their respective gene therapies—bluebird bio or partners Vertex Pharmaceuti
After years of missteps in developing and commercializing its coronavirus shot, Novavax is turning to one of the biopharma industry's most experienced vaccine companies to help salvage its COVID efforts: Sanofi.
(833) 317-6278 
